Built on the authoritative federal record
The primary sources, named on every page.
These are the federal agencies whose public datasets Fonteum ingests and attributes — the issuing authorities, not customers or partners. Every figure on the site links back to one of them.
See the full source registry, with license and refresh cadence for each →
Reproducible by design
Every figure traces to its federal source.
14-tuple provenance
Every rendered fact ties to a source URL, dataset ID, snapshot date, row key, and SHA-256 — the full chain-of-custody record.
Reproducible SQL
Each study ships the exact query behind its figures, run against the cited federal snapshot. Re-run it yourself.
Daily reconciliation
Published counts are reconciled against the upstream federal datasets on a daily cadence, with drift logged.
Named medical review
Reviewed by Jennifer Montecillo, MD, medical reviewer. Non-practicing medical reviewer.
Two doors
Use the free API and open data
Query providers, facilities, sanctions, and quality scores — each field carrying its federal source. Self-serve, no call to start.
Talk to us
Managed pilots, enterprise terms, and audit-ready, signed attestation packages for compliance, risk, and research teams.
The substrate, by the numbers
Cross-source identity
National Provider Identifier 1003073958 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1003073958 | Registry identity — dermatologist, taxonomy 207N00000X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1003073958 | 36 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1003073958 | 24 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity a5da342f… | Canonical resolved node · 4 identifier(s) · 16 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,237 | 35 |
| Education | $8 | 1 |
| Manufacturer | Amount | Records |
|---|---|---|
| Hill Dermaceuticals, Inc. | $337 | 1 |
| Abbvie Inc. | $182 | 8 |
| Galderma Laboratories, L.P. | $174 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Humira Pen(Adalimumab) | 11 | $76,265 |
| Otezla(Apremilast) | 12 | $58,596 |
| Fluorouracil | 152 | $9,925 |
| Tacrolimus | 49 | $7,500 |
| Clobetasol Propionate | 73 | $5,410 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Hill Dermaceuticals, Inc. (FL) | cms_open_payments |
| ← pays | Janssen Biotech, Inc. (PA) | cms_open_payments |
| ← pays | Novartis Pharmaceuticals Corporation (NJ) | cms_open_payments |
| ← pays | Biofrontera Inc. (MA) | cms_open_payments |
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| ← pays | Regeneron Healthcare Solutions, Inc. (NY) | cms_open_payments |
| ← pays | Arcutis Biotherapeutics, Inc. (CA) | cms_open_payments |
| ← pays | Dermavant Sciences, Inc. (CA) | cms_open_payments |
| ← pays | Pfizer Inc. (NY) | cms_open_payments |
| ← pays | Lilly Usa, Llc (IN) | cms_open_payments |
| ← pays | Genzyme Corporation (MA) | cms_open_payments |
| ← pays | Incyte Corporation (DE) | cms_open_payments |
| ← pays | Galderma Laboratories, L.P. (TX) | cms_open_payments |
| ← pays | Revance Therapeutics, Inc. (TN) | cms_open_payments |
| ← pays | Leo Pharma Inc. (NJ) | cms_open_payments |
Record history
Every field on this record is stored bitemporally — both when the fact was true in the world and when Fonteum recorded it. Open the time-travel view to reconstruct this record as of any past date, or to read each field with the source and dates behind it.
| 8 |
| Genzyme Corporation | $90 | 3 |
| Lilly Usa, Llc | $73 | 1 |